Skip to main content
Erschienen in: Breast Cancer Research and Treatment 1/2012

01.05.2012 | Epidemiology

Willingness to use tamoxifen to prevent breast cancer among diverse women

verfasst von: Celia Patricia Kaplan, Sue E. Kim, Sabrina T. Wong, George F. Sawaya, Judith M. E. Walsh, Eliseo J. Pérez-Stable

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 1/2012

Einloggen, um Zugang zu erhalten

Abstract

Use of chemoprevention to prevent development of breast cancer among high-risk women has been limited despite clinical evidence of its benefit. Our goals were to determine whether knowledge of the benefits and risks of tamoxifen affects a woman’s willingness to take it to prevent breast cancer, to define factors associated with willingness to take tamoxifen, and to evaluate race/ethnic differences. Women, ages 50–80, who identified as African American, Asian, Latina, or White, and who had at least one visit to a primary care physician in the previous 2 years, were recruited from ambulatory practices. After a screening telephone survey, women completed an in-person interview in their preferred language. Multivariate regression models were constructed to examine the associations of demographic characteristics, numeracy, breast cancer history, and health knowledge with willingness to take tamoxifen. Over 40% of the women reported they would likely take tamoxifen if determined to be at high risk, and 31% would be somewhat likely to do so. Asian women, those with no insurance, and those with less than high school education were significantly more likely to be willing to take tamoxifen. Higher scores on numeracy and on breast cancer knowledge were also associated with willingness to take tamoxifen. A higher tamoxifen knowledge score was inversely related to willingness to take the drug. Factors affecting women’s willingness to take breast cancer chemoprevention drugs vary and are not determined solely by knowledge of risk/benefit or risk perception.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ (2007) Cancer statistics, 2007. CA Cancer J Clin 57(1):43–66PubMedCrossRef Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ (2007) Cancer statistics, 2007. CA Cancer J Clin 57(1):43–66PubMedCrossRef
2.
Zurück zum Zitat Chlebowski RT (2002) Breast cancer risk reduction: strategies for women at increased risk. Annu Rev Med 53:519–540PubMedCrossRef Chlebowski RT (2002) Breast cancer risk reduction: strategies for women at increased risk. Annu Rev Med 53:519–540PubMedCrossRef
3.
Zurück zum Zitat AHRQ (2007) The guide to clinical preventive services. Recommendations of the U.S. preventive services task force. The Agency for Healthcare Research and Quality AHRQ (2007) The guide to clinical preventive services. Recommendations of the U.S. preventive services task force. The Agency for Healthcare Research and Quality
4.
Zurück zum Zitat Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, Vogel V, Robidoux A, Dimitrov N, Atkins J et al (1998) Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90(18):1371–1388PubMedCrossRef Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, Vogel V, Robidoux A, Dimitrov N, Atkins J et al (1998) Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90(18):1371–1388PubMedCrossRef
5.
Zurück zum Zitat Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN, Bevers TB, Fehrenbacher L, Pajon ER Jr, Wade JL 3rd et al (2006) Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP study of tamoxifen and raloxifene (STAR) P-2 trial. JAMA 295(23):2727–2741PubMedCrossRef Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN, Bevers TB, Fehrenbacher L, Pajon ER Jr, Wade JL 3rd et al (2006) Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP study of tamoxifen and raloxifene (STAR) P-2 trial. JAMA 295(23):2727–2741PubMedCrossRef
6.
Zurück zum Zitat Bastian L, Lipkus I, Kuchibhatla M, Weng H, Halabi S, Ryan P, Skinner C, Rimer B (2001) Women’s interest in chemoprevention for breast cancer. Arch Intern Med 161:1639–1644PubMedCrossRef Bastian L, Lipkus I, Kuchibhatla M, Weng H, Halabi S, Ryan P, Skinner C, Rimer B (2001) Women’s interest in chemoprevention for breast cancer. Arch Intern Med 161:1639–1644PubMedCrossRef
7.
Zurück zum Zitat Taylor R, Taguchi K (2005) Tamoxifen for breast cancer chemoprevention: low uptake by high-risk women after evaluation of a breast lump. Ann Fam Med 3(3):242–247PubMedCrossRef Taylor R, Taguchi K (2005) Tamoxifen for breast cancer chemoprevention: low uptake by high-risk women after evaluation of a breast lump. Ann Fam Med 3(3):242–247PubMedCrossRef
8.
Zurück zum Zitat Bober SL, Hoke LA, Duda RB, Regan MM, Tung NM (2004) Decision-making about tamoxifen in women at high risk for breast cancer: clinical and psychological factors. J Clin Oncol 22(24):4951–4957PubMedCrossRef Bober SL, Hoke LA, Duda RB, Regan MM, Tung NM (2004) Decision-making about tamoxifen in women at high risk for breast cancer: clinical and psychological factors. J Clin Oncol 22(24):4951–4957PubMedCrossRef
9.
Zurück zum Zitat Melnikow J, Paterniti D, Azari R, Kuenneth C, Birch S, Kuppermann M, Nuovo J, Keyzer J, Henderson S (2005) Preferences of women evaluating risks of tamoxifen (POWER) study of preferences for tamoxifen for breast cancer risk reduction. Cancer 103(10):1996–2005PubMedCrossRef Melnikow J, Paterniti D, Azari R, Kuenneth C, Birch S, Kuppermann M, Nuovo J, Keyzer J, Henderson S (2005) Preferences of women evaluating risks of tamoxifen (POWER) study of preferences for tamoxifen for breast cancer risk reduction. Cancer 103(10):1996–2005PubMedCrossRef
10.
Zurück zum Zitat Tchou J, Hou N, Rademaker A, Jordan VC, Morrow M (2004) Acceptance of tamoxifen chemoprevention by physicians and women at risk. Cancer 100(9):1800–1806PubMedCrossRef Tchou J, Hou N, Rademaker A, Jordan VC, Morrow M (2004) Acceptance of tamoxifen chemoprevention by physicians and women at risk. Cancer 100(9):1800–1806PubMedCrossRef
11.
Zurück zum Zitat Kaplan C, Haas J, Pérez-Stable EJ, Gregorich S, Somkin C, Des Jarlais G, Kerlikowske K (2006) Breast cancer risk reduction options: awareness, discussion, and use among women from four ethnic groups. Cancer Epidemiol Biomark Prev 15(1):162–166CrossRef Kaplan C, Haas J, Pérez-Stable EJ, Gregorich S, Somkin C, Des Jarlais G, Kerlikowske K (2006) Breast cancer risk reduction options: awareness, discussion, and use among women from four ethnic groups. Cancer Epidemiol Biomark Prev 15(1):162–166CrossRef
12.
Zurück zum Zitat Kim S, Pérez-Stable EJ, Wong S, Gregorich S, Sawaya G, Walsh J, Kaplan C (2008) Association between cancer risk perception and screening behavior among diverse women. Arch Intern Med 168(7):728–734PubMedCrossRef Kim S, Pérez-Stable EJ, Wong S, Gregorich S, Sawaya G, Walsh J, Kaplan C (2008) Association between cancer risk perception and screening behavior among diverse women. Arch Intern Med 168(7):728–734PubMedCrossRef
13.
Zurück zum Zitat Fagerlin A, Zikmund-Fisher B, Smith DM, Vijayan N, Derry H, McClure J, Greene S, Stark A, Alford S, Lantz P et al (2010) Women’s decisions regarding tamoxifen for breast cancer prevention: responses to a tailored decision aid. Breast Cancer Res Treat 119:613–620PubMedCrossRef Fagerlin A, Zikmund-Fisher B, Smith DM, Vijayan N, Derry H, McClure J, Greene S, Stark A, Alford S, Lantz P et al (2010) Women’s decisions regarding tamoxifen for breast cancer prevention: responses to a tailored decision aid. Breast Cancer Res Treat 119:613–620PubMedCrossRef
14.
Zurück zum Zitat Denberg TD, Wong S, Beattie A (2005) Women’s misconceptions about cancer screening: implications for informed decision-making. Patient Educ Couns 57(3):280–285PubMedCrossRef Denberg TD, Wong S, Beattie A (2005) Women’s misconceptions about cancer screening: implications for informed decision-making. Patient Educ Couns 57(3):280–285PubMedCrossRef
15.
Zurück zum Zitat Harris-Kojetin LD, Fowler FJ Jr, Brown JA, Schnaier JA, Sweeny SF (1999) The use of cognitive testing to develop and evaluate CAHPS 1.0 core survey items. Consumer assessment of health plans study. Med Care 37(3 Suppl):MS10–MS21PubMedCrossRef Harris-Kojetin LD, Fowler FJ Jr, Brown JA, Schnaier JA, Sweeny SF (1999) The use of cognitive testing to develop and evaluate CAHPS 1.0 core survey items. Consumer assessment of health plans study. Med Care 37(3 Suppl):MS10–MS21PubMedCrossRef
16.
Zurück zum Zitat Schwartz L, Woloshin S, Black W, Welch H (1997) The role of numeracy in understanding the benefit of screening mammography. Ann Intern Med 127(11):966–972PubMed Schwartz L, Woloshin S, Black W, Welch H (1997) The role of numeracy in understanding the benefit of screening mammography. Ann Intern Med 127(11):966–972PubMed
17.
Zurück zum Zitat Wong S, Pérez-Stable EJ, Kim S, Gregorich S, Sawaya G, Walsh J, Washington A, Kaplan C (2012) Using visual displays to communicate risk of cancer to diverse women. Patient Educ Couns. doi:10.1016/j.pec.2011.11.014 Wong S, Pérez-Stable EJ, Kim S, Gregorich S, Sawaya G, Walsh J, Washington A, Kaplan C (2012) Using visual displays to communicate risk of cancer to diverse women. Patient Educ Couns. doi:10.​1016/​j.​pec.​2011.​11.​014
18.
Zurück zum Zitat Port ER, Montgomery LL, Heerdt AS, Borgen PI (2001) Patient reluctance toward tamoxifen use for breast cancer primary prevention. Ann Surg Oncol 8(7):580–585PubMedCrossRef Port ER, Montgomery LL, Heerdt AS, Borgen PI (2001) Patient reluctance toward tamoxifen use for breast cancer primary prevention. Ann Surg Oncol 8(7):580–585PubMedCrossRef
19.
Zurück zum Zitat Haas J, Kaplan C, Des Jarlais G, Gildengoin V, Pérez-Stable EJ, Kerlikowske K (2005) Perceived risk of breast cancer among women at average and increased risk. J Womens Health (Larchmt) 14(9):845–851CrossRef Haas J, Kaplan C, Des Jarlais G, Gildengoin V, Pérez-Stable EJ, Kerlikowske K (2005) Perceived risk of breast cancer among women at average and increased risk. J Womens Health (Larchmt) 14(9):845–851CrossRef
20.
Zurück zum Zitat Wong ST, Chen W, Bottorff JL, Hislop TG (2008) Treatment decision making among Chinese women with DCIS. J Psychosoc Oncol 26(4):53–73PubMedCrossRef Wong ST, Chen W, Bottorff JL, Hislop TG (2008) Treatment decision making among Chinese women with DCIS. J Psychosoc Oncol 26(4):53–73PubMedCrossRef
Metadaten
Titel
Willingness to use tamoxifen to prevent breast cancer among diverse women
verfasst von
Celia Patricia Kaplan
Sue E. Kim
Sabrina T. Wong
George F. Sawaya
Judith M. E. Walsh
Eliseo J. Pérez-Stable
Publikationsdatum
01.05.2012
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 1/2012
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-012-1960-5

Weitere Artikel der Ausgabe 1/2012

Breast Cancer Research and Treatment 1/2012 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.